Self-Assembling Peptide Hydrogels Support Stromal Vascular Fraction Viability to Promote In Vivo Nerve Regeneration.
McMorrow LA., Llewellyn S., McSweeney J., Faroni A., Miller AF., Saiani A.
Animal Study, published in Adv Healthc Mater (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Adv Healthc Mater (2025)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41367103
- PMCID
- PMC12988569
- DOI
- 10.1002/adhm.202503987
Abstract (original English)
Autograft, the gold standard in nerve reconstruction, outperforms the alternatives of acellular allograft/nerve conduits likely due to the transplanted Schwann cell population within. The stromal vascular fraction (SVF) is a heterogenous cell isolate, that may improve nerve regeneration outcomes when transplanted at the site of a nerve defect. Self-Assembling Peptide hydrogels (SAPH) are synthetic materials derived from short chains of biological amino acids. They are safe, injectable hydrogels whose charge and mechanical properties are easily tuned. Our hypothesis is that SVF, when transplanted within an SAPH, tailored toward nerve regeneration and SVF viability, will improve outcomes of nerve regeneration. In vitro modelling is used to select SAPH that support the viable 3D culture of SVF and outgrowth from neuronal explants. In vivo experimentation with a 10 mm rat sciatic nerve defect demonstrated that SVF, when delivered within a conduit, in a positively charged, mechanically optimized SAPH, significantly improved functional motor and sensory recovery compared to collagen controls and SAPH without SVF and is at least as good as autograft. Using male SVF, qPCR identification of Y chromosomal DNA suggested that SVF transplanted in SAPH has increased longevity when compared to SVF transplanted in collagen gel.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.